antiplatelet effects of garlic

Phase 2

• Conditions: agents affecting blood constituents.; Other and unspecified agents affecting blood constituents

• Registration Number: IRCT2012073110453N1
• Lead Sponsor: Pharmaceutical Siences Reseaserch

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

Exclusion criteria applied to individuals who had cardiovascular disease, been using aspirin, clopidogrel and nonsteroidal anti inflammatory drugs ( NSAIDS) in the last 2 weeks ago , thrombocytopenia(platelet<100 × 10 3 platelets /mm3 ), anemia(hemoglobin<10g/dl),abnormal lipid profile[total chlosterol = 200 mg/dl , LDL-C =100mg/dl , TG = 200 mg/dl HDL= 45 mg/dl(male) and = 55 mg/dl(female) ], Diabetes mellitus (FBS = 126 mg/ dl confirmed by repeating the test), and renal failure[Serum creatinine = 2mg/dl (female) and Serum creatinine=2.5 mg/dl (male)]
inclusion criteria : 62 healthy individuals(non diabetic ? normal lipid profile ? without any cardiovascular disease and coagulation disordes ?non used aspirin, clopidogrel and nonsteroidal anti inflammatory drugs ( NSAIDS) in the last 2 weeks ago aged 20-50 years old were enrolled in this clinical trial.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Platelet aggregation. Timepoint: 3 months. Method of measurement: Light transmission aggregometer.